Optimal treatment of social phobia: systematic review and meta-analysis
- PMID: 22665997
- PMCID: PMC3363138
- DOI: 10.2147/NDT.S23317
Optimal treatment of social phobia: systematic review and meta-analysis
Abstract
This article proposes a number of recommendations for the treatment of generalized social phobia, based on a systematic literature review and meta-analysis. An optimal treatment regimen would include a combination of medication and psychotherapy, along with an assertive clinical management program. For medications, selective serotonin reuptake inhibitors and dual serotonin-norepinephrine reuptake inhibitors are first-line choices based on their efficacy and tolerability profiles. The nonselective monoamine oxidase inhibitor, phenelzine, may be more potent than these two drug classes, but because of its food and drug interaction liabilities, its use should be restricted to patients not responding to selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. There are other medication classes with demonstrated efficacy in social phobia (benzodiazepines, antipsychotics, alpha-2-delta ligands), but due to limited published clinical trial data and the potential for dependence and withdrawal issues with benzodiazepines, it is unclear how best to incorporate these drugs into treatment regimens. There are very few clinical trials on the use of combined medications. Cognitive behavior therapy appears to be more effective than other evidence-based psychological techniques, and its effects appear to be more enduring than those of pharmacotherapy. There is some evidence, albeit limited to certain drug classes, that the combination of medication and cognitive behavior therapy may be more effective than either strategy used alone. Generalized social phobia is a chronic disorder, and many patients will require long-term support and treatment.
Keywords: antidepressant; cognitive behavior therapy; psychotherapy; social anxiety disorder; social phobia.
Figures








Similar articles
-
[Neurobiology and pharmacotherapy of social phobia].Encephale. 2004 Jul-Aug;30(4):301-13. doi: 10.1016/s0013-7006(04)95442-5. Encephale. 2004. PMID: 15538306 Review. French.
-
WCA recommendations for the long-term treatment of social phobia.CNS Spectr. 2003 Aug;8(8 Suppl 1):40-52. doi: 10.1017/s1092852900006933. CNS Spectr. 2003. PMID: 14767397 Review.
-
International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997.Depress Anxiety. 1999;9(3):107-16. doi: 10.1002/(sici)1520-6394(1999)9:33.0.co;2-t. Depress Anxiety. 1999. PMID: 10356648
-
Pharmacotherapy for social phobia.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001206. doi: 10.1002/14651858.CD001206.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2017 Oct 19;10:CD001206. doi: 10.1002/14651858.CD001206.pub3. PMID: 15495010 Updated. Review.
-
Medication therapy for social phobia.J Clin Psychiatry. 1994 Jun;55 Suppl:33-7. J Clin Psychiatry. 1994. PMID: 8077172 Review.
Cited by
-
Concomitant treatment with sertraline and social skills training improves social skills acquisition in social anxiety disorder: A double-blind, randomized controlled trial.PLoS One. 2018 Oct 29;13(10):e0205809. doi: 10.1371/journal.pone.0205809. eCollection 2018. PLoS One. 2018. PMID: 30372482 Free PMC article. Clinical Trial.
-
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.Neurol Int. 2021 Aug 5;13(3):387-401. doi: 10.3390/neurolint13030038. Neurol Int. 2021. PMID: 34449705 Free PMC article. Review.
-
Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.Sci Rep. 2023 Feb 11;13(1):2466. doi: 10.1038/s41598-023-29763-x. Sci Rep. 2023. PMID: 36774449 Free PMC article.
-
Interpersonal neural synchrony and mental disorders: unlocking potential pathways for clinical interventions.Front Neurosci. 2024 Mar 11;18:1286130. doi: 10.3389/fnins.2024.1286130. eCollection 2024. Front Neurosci. 2024. PMID: 38529267 Free PMC article.
-
The Cost Effectiveness of Psychological and Pharmacological Interventions for Social Anxiety Disorder: A Model-Based Economic Analysis.PLoS One. 2015 Oct 27;10(10):e0140704. doi: 10.1371/journal.pone.0140704. eCollection 2015. PLoS One. 2015. PMID: 26506554 Free PMC article.
References
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders. 4th ed. Washington DC: American Psychiatric Association; 2000.
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
-
- Magee WJ, Eaton WW, Wittchen H-U, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53(2):159–168. - PubMed
-
- Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings. Am J Psychiatry. 2000;157(10):1606–1613. - PubMed
LinkOut - more resources
Full Text Sources